Ad is loading...
GOSS
Price
$0.74
Change
-$0.03 (-3.90%)
Updated
Nov 15 closing price
124 days until earnings call
OCX
Price
$2.61
Change
-$0.19 (-6.79%)
Updated
Nov 15 closing price
Ad is loading...

GOSS vs OCX

Header iconGOSS vs OCX Comparison
Open Charts GOSS vs OCXBanner chart's image
Gossamer Bio
Price$0.74
Change-$0.03 (-3.90%)
Volume$620.91K
CapitalizationN/A
Oncocyte
Price$2.61
Change-$0.19 (-6.79%)
Volume$57.29K
CapitalizationN/A
GOSS vs OCX Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GOSS vs. OCX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Sell and OCX is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (GOSS: $0.74 vs. OCX: $2.61)
Brand notoriety: GOSS and OCX are both not notable
GOSS represents the Biotechnology, while OCX is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GOSS: 71% vs. OCX: 140%
Market capitalization -- GOSS: $167.71M vs. OCX: $24.2M
GOSS [@Biotechnology] is valued at $167.71M. OCX’s [@Medical Specialties] market capitalization is $24.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileOCX’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • OCX’s FA Score: 0 green, 5 red.
According to our system of comparison, GOSS is a better buy in the long-term than OCX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish.

  • GOSS’s TA Score: 4 bullish, 7 bearish.

Price Growth

GOSS (@Biotechnology) experienced а -15.79% price change this week, while OCX (@Medical Specialties) price change was -8.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.

Reported Earning Dates

GOSS is expected to report earnings on Mar 21, 2025.

OCX is expected to report earnings on Nov 09, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (-4.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($168M) has a higher market cap than OCX($24.2M). OCX YTD gains are higher at: 4.400 vs. GOSS (-18.893). OCX has higher annual earnings (EBITDA): -10.44M vs. GOSS (-59.72M). GOSS has more cash in the bank: 354M vs. OCX (14.2M). OCX has less debt than GOSS: OCX (3.07M) vs GOSS (199M). GOSS has higher revenues than OCX: GOSS (95.8M) vs OCX (1.46M).
GOSSOCXGOSS / OCX
Capitalization168M24.2M694%
EBITDA-59.72M-10.44M572%
Gain YTD-18.8934.400-429%
P/E RatioN/A4.56-
Revenue95.8M1.46M6,548%
Total Cash354M14.2M2,493%
Total Debt199M3.07M6,474%
FUNDAMENTALS RATINGS
OCX: Fundamental Ratings
OCX
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
82
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GOSS
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
MACD
ODDS (%)
Bearish Trend 7 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 24 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SATS22.790.80
+3.64%
EchoStar Corp
FITB46.99-0.27
-0.57%
Fifth Third Bancorp
GPMT3.26-0.09
-2.69%
Granite Point Mortgage Trust
NG3.39-0.11
-3.14%
NovaGold Resources
BTM2.00-0.43
-17.70%
Bitcoin Depot

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
-3.88%
MEIP - GOSS
46%
Loosely correlated
-2.99%
CGEM - GOSS
45%
Loosely correlated
-9.41%
SYRE - GOSS
41%
Loosely correlated
-6.62%
APVO - GOSS
41%
Loosely correlated
-12.45%
VIR - GOSS
41%
Loosely correlated
-7.29%
More

OCX and

Correlation & Price change

A.I.dvisor tells us that OCX and FATE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCX and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCX
1D Price
Change %
OCX100%
-6.79%
FATE - OCX
31%
Poorly correlated
-2.88%
FONR - OCX
31%
Poorly correlated
-2.97%
GOSS - OCX
29%
Poorly correlated
-3.88%
BMRN - OCX
29%
Poorly correlated
-3.32%
CRIS - OCX
28%
Poorly correlated
-0.75%
More